US20210361734A1 - Compositions and methods for potentiating immune checkpoint inhibitor therapy - Google Patents

Compositions and methods for potentiating immune checkpoint inhibitor therapy Download PDF

Info

Publication number: US20210361734A1
Authority: US; United States
Prior art keywords: larazotide; derivative; administered; checkpoint inhibitor; immune checkpoint
Prior art date: 2018-03-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US16/982,115

Other languages

English (en)

Inventor

Jay Madan

Sandeep Laumas

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

9 Meters Biopharma Inc

Original Assignee

9 Meters Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-03-19

Filing date

2019-03-19

Publication date

2021-11-25

2019-03-19 Application filed by 9 Meters Biopharma Inc filed Critical 9 Meters Biopharma Inc

2019-03-19 Priority to US16/982,115 priority Critical patent/US20210361734A1/en

2021-02-10 Priority to US17/172,387 priority patent/US20210169968A1/en

2021-05-26 Assigned to 9 METERS BIOPHARMA, INC. reassignment 9 METERS BIOPHARMA, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: INNOVATE BIOPHARMACEUTICALS, INC.

2021-05-26 Assigned to INNOVATE BIOPHARMACEUTICALS, INC. reassignment INNOVATE BIOPHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAUMAS, SANDEEP

2021-05-26 Assigned to 9 METERS BIOPHARMA, INC. reassignment 9 METERS BIOPHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MADAN, Jay

2021-11-25 Publication of US20210361734A1 publication Critical patent/US20210361734A1/en

2023-04-10 Assigned to HIGH TRAIL SPECIAL SITUATIONS LLC reassignment HIGH TRAIL SPECIAL SITUATIONS LLC INTELLECTUAL PROPERTY SECURITY AGREEMENT Assignors: 9 METERS BIOPHARMA, INC., NAIA RARE DISEASES, LLC

Status Abandoned legal-status Critical Current

Links

229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims abstract description 56
239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims abstract description 56
238000002560 therapeutic procedure Methods 0.000 title claims abstract description 49
108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims abstract description 40
102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims abstract description 40
238000000034 method Methods 0.000 title claims abstract description 40
239000000203 mixture Substances 0.000 title claims abstract description 40
230000003389 potentiating effect Effects 0.000 title claims abstract description 7
ORFLZNAGUTZRLQ-ZMBVWFSWSA-N Larazotide Chemical compound NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O ORFLZNAGUTZRLQ-ZMBVWFSWSA-N 0.000 claims abstract description 99
229950000060 larazotide Drugs 0.000 claims abstract description 94
206010028980 Neoplasm Diseases 0.000 claims abstract description 35
201000011510 cancer Diseases 0.000 claims abstract description 29
230000003111 delayed effect Effects 0.000 claims description 27
238000009472 formulation Methods 0.000 claims description 21
238000013268 sustained release Methods 0.000 claims description 16
210000001035 gastrointestinal tract Anatomy 0.000 claims description 15
239000012730 sustained-release form Substances 0.000 claims description 13
210000002429 large intestine Anatomy 0.000 claims description 12
210000001198 duodenum Anatomy 0.000 claims description 11
210000003405 ileum Anatomy 0.000 claims description 11
210000001630 jejunum Anatomy 0.000 claims description 11
230000004044 response Effects 0.000 claims description 11
241001515965 unidentified phage Species 0.000 claims description 11
102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 9
239000006041 probiotic Substances 0.000 claims description 9
235000018291 probiotics Nutrition 0.000 claims description 9
101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 8
108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 8
230000000529 probiotic effect Effects 0.000 claims description 8
108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
239000002775 capsule Substances 0.000 claims description 5
230000000977 initiatory effect Effects 0.000 claims description 5
229960003301 nivolumab Drugs 0.000 claims description 5
229960002621 pembrolizumab Drugs 0.000 claims description 5
108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
229960005386 ipilimumab Drugs 0.000 claims description 4
229950007217 tremelimumab Drugs 0.000 claims description 4
101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 3
102000017578 LAG3 Human genes 0.000 claims description 3
101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
102000008096 B7-H1 Antigen Human genes 0.000 claims 2
102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 description 22
108090000765 processed proteins & peptides Proteins 0.000 description 20
239000002245 particle Substances 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 14
238000000576 coating method Methods 0.000 description 14
229920000642 polymer Polymers 0.000 description 14
IOLWXFWVYYCVTJ-NRPADANISA-N Cys-Val-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N IOLWXFWVYYCVTJ-NRPADANISA-N 0.000 description 12
MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 12
108010047857 aspartylglycine Proteins 0.000 description 12
239000011248 coating agent Substances 0.000 description 12
210000001072 colon Anatomy 0.000 description 12
239000012530 fluid Substances 0.000 description 12
108010029020 prolylglycine Proteins 0.000 description 12
210000000813 small intestine Anatomy 0.000 description 12
210000001578 tight junction Anatomy 0.000 description 10
230000000968 intestinal effect Effects 0.000 description 9
244000005700 microbiome Species 0.000 description 9
101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 8
235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 7
241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 description 7
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 7
210000004534 cecum Anatomy 0.000 description 7
229920003176 water-insoluble polymer Polymers 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
229920003134 Eudragit® polymer Polymers 0.000 description 6
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
238000013270 controlled release Methods 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
230000002496 gastric effect Effects 0.000 description 5
229940004208 lactobacillus bulgaricus Drugs 0.000 description 5
230000035699 permeability Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 4
OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 4
WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 4
XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 4
OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 4
240000001046 Lactobacillus acidophilus Species 0.000 description 4
235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
102000000591 Tight Junction Proteins Human genes 0.000 description 4
108010002321 Tight Junction Proteins Proteins 0.000 description 4
-1 amino acid amino acid Chemical class 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
230000001174 ascending effect Effects 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
108010067216 glycyl-glycyl-glycine Proteins 0.000 description 4
108010026364 glycyl-glycyl-leucine Proteins 0.000 description 4
108010078326 glycyl-glycyl-valine Proteins 0.000 description 4
210000004347 intestinal mucosa Anatomy 0.000 description 4
229940039695 lactobacillus acidophilus Drugs 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 3
241000193163 Clostridioides difficile Species 0.000 description 3
241000186660 Lactobacillus Species 0.000 description 3
244000199866 Lactobacillus casei Species 0.000 description 3
235000013958 Lactobacillus casei Nutrition 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
241000194020 Streptococcus thermophilus Species 0.000 description 3
210000001815 ascending colon Anatomy 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
210000001731 descending colon Anatomy 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
229940039696 lactobacillus Drugs 0.000 description 3
229940017800 lactobacillus casei Drugs 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
208000037819 metastatic cancer Diseases 0.000 description 3
208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
210000000664 rectum Anatomy 0.000 description 3
210000001599 sigmoid colon Anatomy 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
210000003384 transverse colon Anatomy 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
241000606125 Bacteroides Species 0.000 description 2
241000186000 Bifidobacterium Species 0.000 description 2
241000186016 Bifidobacterium bifidum Species 0.000 description 2
241000186012 Bifidobacterium breve Species 0.000 description 2
241001608472 Bifidobacterium longum Species 0.000 description 2
241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
102100038078 CD276 antigen Human genes 0.000 description 2
241000193403 Clostridium Species 0.000 description 2
241000193171 Clostridium butyricum Species 0.000 description 2
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
241000588722 Escherichia Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
241000186394 Eubacterium Species 0.000 description 2
229920003143 Eudragit® FS 30 D Polymers 0.000 description 2
241001608234 Faecalibacterium Species 0.000 description 2
241000589989 Helicobacter Species 0.000 description 2
101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 2
240000006024 Lactobacillus plantarum Species 0.000 description 2
235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
102100033272 Macrophage receptor MARCO Human genes 0.000 description 2
101710089357 Macrophage receptor MARCO Proteins 0.000 description 2
206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
241000206591 Peptococcus Species 0.000 description 2
241000191992 Peptostreptococcus Species 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
241000192031 Ruminococcus Species 0.000 description 2
241000235070 Saccharomyces Species 0.000 description 2
206010041067 Small cell lung cancer Diseases 0.000 description 2
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
241000194017 Streptococcus Species 0.000 description 2
159000000021 acetate salts Chemical class 0.000 description 2
229940081735 acetylcellulose Drugs 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000004075 alteration Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
229940002008 bifidobacterium bifidum Drugs 0.000 description 2
229940004120 bifidobacterium infantis Drugs 0.000 description 2
229940009291 bifidobacterium longum Drugs 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
239000000599 controlled substance Substances 0.000 description 2
239000007771 core particle Substances 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
108010050848 glycylleucine Proteins 0.000 description 2
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000007358 intestinal barrier function Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229940072205 lactobacillus plantarum Drugs 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000002101 lytic effect Effects 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
208000021039 metastatic melanoma Diseases 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
239000001814 pectin Substances 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
229960002181 saccharomyces boulardii Drugs 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
208000000587 small cell lung carcinoma Diseases 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000033 toxigenic Toxicity 0.000 description 2
230000001551 toxigenic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000235172 Bullera Species 0.000 description 1
102100038077 CD226 antigen Human genes 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
102100025221 CD70 antigen Human genes 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241001137855 Caudovirales Species 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241001123633 Galactomyces Species 0.000 description 1
102100031351 Galectin-9 Human genes 0.000 description 1
101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
206010066476 Haematological malignancy Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
102100021317 Inducible T-cell costimulator Human genes 0.000 description 1
101710205775 Inducible T-cell costimulator Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
241000218588 Lactobacillus rhamnosus Species 0.000 description 1
241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
241000701553 Myoviridae Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241000228143 Penicillium Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241001136503 Pleospora Species 0.000 description 1
241000702072 Podoviridae Species 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
241000223252 Rhodotorula Species 0.000 description 1
241000221662 Sclerotinia Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
241000702202 Siphoviridae Species 0.000 description 1
229920002125 Sokalan® Chemical class 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000194024 Streptococcus salivarius Species 0.000 description 1
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
241000222354 Trametes Species 0.000 description 1
102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
101150110932 US19 gene Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
238000007792 addition Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940009289 bifidobacterium lactis Drugs 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229920001688 coating polymer Polymers 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000006196 drop Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940115473 florajen3 Drugs 0.000 description 1
IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
230000037406 food intake Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
244000005709 gut microbiome Species 0.000 description 1
210000005205 gut mucosa Anatomy 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
210000005027 intestinal barrier Anatomy 0.000 description 1
230000003870 intestinal permeability Effects 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
230000001320 lysogenic effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
208000011645 metastatic carcinoma Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
244000005706 microflora Species 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000004584 polyacrylic acid Chemical class 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
229920001290 polyvinyl ester Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
125000005591 trimellitate group Chemical group 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
229940055760 yervoy Drugs 0.000 description 1
229940006486 zinc cation Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

suitable water insoluble polymers include, for example, lacquer, and acrylic and/or methacrylic ester polymers, polymers or copolymers of acrylate or methacrylate having a low quaternary ammonium content, or mixture thereof and the like.
suitable water insoluble polymers include, for example, EUDRAGIT RS®, EUDRAGIT RL®, EUDRAGIT NE®, polyvinyl esters, polyvinyl acetals, polyacrylic acid esters, butadiene styrene copolymers, and the like.
the delayed-release coating comprises a combination of any of the foregoing water insoluble polymers.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

US16/982,115 2018-03-19 2019-03-19 Compositions and methods for potentiating immune checkpoint inhibitor therapy Abandoned US20210361734A1 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
US16/982,115 US20210361734A1 (en)	2018-03-19	2019-03-19	Compositions and methods for potentiating immune checkpoint inhibitor therapy
US17/172,387 US20210169968A1 (en)	2018-03-19	2021-02-10	Compositions and methods for potentiating immune checkpoint inhibitor therapy

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201862644723P	2018-03-19	2018-03-19
PCT/US2019/022885 WO2019183036A1 (fr)	2018-03-19	2019-03-19	Compositions et méthodes pour potentialiser une thérapie par inhibiteur de point de contrôle immunitaire
US16/982,115 US20210361734A1 (en)	2018-03-19	2019-03-19	Compositions and methods for potentiating immune checkpoint inhibitor therapy

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/US2019/022885 A-371-Of-International WO2019183036A1 (fr)	2018-03-19	2019-03-19	Compositions et méthodes pour potentialiser une thérapie par inhibiteur de point de contrôle immunitaire

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US17/172,387 Continuation-In-Part US20210169968A1 (en)	2018-03-19	2021-02-10	Compositions and methods for potentiating immune checkpoint inhibitor therapy

Publications (1)

Publication Number	Publication Date
US20210361734A1 true US20210361734A1 (en)	2021-11-25

Family

ID=67987489

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
US16/982,115 Abandoned US20210361734A1 (en)	2018-03-19	2019-03-19	Compositions and methods for potentiating immune checkpoint inhibitor therapy
US17/239,056 Active US11278587B2 (en)	2018-03-19	2021-04-23	Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
US17/239,056 Active US11278587B2 (en)	2018-03-19	2021-04-23	Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors

Country Status (2)

Country	Link
US (2)	US20210361734A1 (fr)
WO (1)	WO2019183036A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2019013648A (es)	2017-05-19	2021-01-08	Wuxi Biologics Shanghai Co Ltd	Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
WO2019165346A1 (fr)	2018-02-23	2019-08-29	Innovate Biopharmaceuticals, Inc.	Composés et méthodes de traitement de la perméabilité des jonctions serrées
BR112021012631A2 (pt)	2018-12-26	2021-12-14	Xilio Dev Inc	Anticorpos anti-ctla4 e métodos de uso dos mesmos
CA3150380A1 (fr) *	2019-08-16	2021-02-25	9 Meters Biopharma, Inc.	Formulations de larazotide
CN115916235A (zh) *	2020-04-15	2023-04-04	九米特生物制药有限公司	包含d-氨基酸的拉瑞唑来衍生物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0707616A2 (pt)	2006-02-09	2011-05-10	Alba Therapuetics Corp	formulaÇÕes para um efetor de junÇço oclusiva
US20090069247A1 (en)	2006-10-06	2009-03-12	Blake Paterson	Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en)	2006-10-26	2011-10-11	Alba Therapeutics Corporation	Materials and methods for the treatment of celiac disease
WO2009006246A1 (fr)	2007-06-29	2009-01-08	Alea Therapeutics Corp.	Utilisation d'antagonistes des jonctions étanches pour traiter une plaie pulmonaire aiguë et le syndrome de détresse respiratoire aiguë
WO2009052489A2 (fr)	2007-10-19	2009-04-23	Alba Therapeutics Corporation	Nouveaux inhibiteurs de l'ouverture des jonctions serrées chez les mammifères
US8957032B2 (en)	2008-05-06	2015-02-17	Alba Therapeutics Corporation	Inhibition of gliadin peptides
EP2927240A1 (fr) *	2008-08-25	2015-10-07	Amplimmune, Inc.	Compositions d'antagonistes pd-1 et procédés d'utilisation
US20120302505A1 (en) *	2011-04-21	2012-11-29	Fetzer Oliver S	Cyclodextrin-based polymers for therapeutic delivery
WO2015154010A1 (fr)	2014-04-04	2015-10-08	Perrow Wendy	Procédés de traitement de la maladie coeliaque avec le larazotide
RS67172B1 (sr) *	2016-03-31	2025-09-30	Biontech Us Inc	Neoantigeni i postupci za njihovu upotrebu
KR20190121785A (ko)	2017-02-10	2019-10-28	이노베이트 바이오파마슈티컬스, 인코포레이티드	장 상피의 투과성과 관련된 질환을 치료하기 위한 조성물 및 방법
WO2018187272A1 (fr) *	2017-04-03	2018-10-11	Gusto Global, Llc	Conception rationnelle d'agents biothérapeutiques d'origine microbienne
WO2019165346A1 (fr)	2018-02-23	2019-08-29	Innovate Biopharmaceuticals, Inc.	Composés et méthodes de traitement de la perméabilité des jonctions serrées
WO2019165345A1 (fr)	2018-02-23	2019-08-29	Innovate Biopharmaceuticals, Inc.	Compositions et méthodes de traitement ou de prévention de la perméabilité paracellulaire intestinale
US20210100868A1 (en)	2018-03-19	2021-04-08	North Carolina State University	Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
US20210069286A1 (en)	2018-04-09	2021-03-11	9 Meters Biopharma, Inc.	Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage
WO2020227341A1 (fr)	2019-05-06	2020-11-12	9 Meters Biopharma, Inc.	Compositions et procédés de traitement du syndrome de sjögren
CA3150380A1 (fr)	2019-08-16	2021-02-25	9 Meters Biopharma, Inc.	Formulations de larazotide

2019
- 2019-03-19 US US16/982,115 patent/US20210361734A1/en not_active Abandoned
- 2019-03-19 WO PCT/US2019/022885 patent/WO2019183036A1/fr not_active Ceased
2021
- 2021-04-23 US US17/239,056 patent/US11278587B2/en active Active

Also Published As

Publication number	Publication date
WO2019183036A1 (fr)	2019-09-26
US20210236586A1 (en)	2021-08-05
US11278587B2 (en)	2022-03-22

Publication	Publication Date	Title
US11278587B2 (en)	2022-03-22	Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors
KR102467968B1 (ko)	2022-11-16	베타-락타마제 제형 및 이의 용도
CN111328284A (zh)	2020-06-23	用于维持和恢复健康的肠道屏障的组合物和方法
Chermesh et al.	2006	Probiotics and the gastrointestinal tract: where are we in 2005?
EP3049070A2 (fr)	2016-08-03	Compositions et méthodes pour le traitement et la prophylaxie de maladies gastro-intestinales
KR20200011619A (ko)	2020-02-03	니코틴산 및/또는 니코틴아미드 및/또는 트립토판을 포함하는 장내 세균총에 유익한 효능을 가진 약학 조성물
US20190358288A1 (en)	2019-11-28	Compositions and methods for treating or preventing environmental enteropathy
US20240263251A1 (en)	2024-08-08	Compositions and methods for providing secondary bile acids to a subject
Al-Toubah et al.	2024	Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
JP6554468B2 (ja)	2019-07-31	ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するため
US20240226187A9 (en)	2024-07-11	Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
US20210169968A1 (en)	2021-06-10	Compositions and methods for potentiating immune checkpoint inhibitor therapy
KR20170122776A (ko)	2017-11-06	마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
US20210100868A1 (en)	2021-04-08	Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
US20230218706A1 (en)	2023-07-13	Larazotide derivatives comprising d-amino acids
CN115697324B (zh)	2025-03-25	栗木鞣花素或其类似物用于抗癌功效和增加对免疫检查点抑制剂的应答的用途
TW202322787A (zh)	2023-06-16	包含細菌和微生物胞外囊泡之固體劑型
WO2022108870A1 (fr)	2022-05-27	Compositions et méthodes de traitement de la fibrose pulmonaire
Karimi et al.	2011	Probiotics in clinical practice as therapeutics against enteric disorders
HK40044298A (en)	2021-09-30	Microbiome related immunotherapies
Sood	2014	Department of Gastroenterology Vandana Midha Department of Medicine Dayanand Medical College and Hospital

Legal Events

Date	Code	Title	Description
2021-05-26	AS	Assignment	Owner name: 9 METERS BIOPHARMA, INC., NORTH CAROLINA Free format text: CHANGE OF NAME;ASSIGNOR:INNOVATE BIOPHARMACEUTICALS, INC.;REEL/FRAME:056396/0451 Effective date: 20200430 Owner name: INNOVATE BIOPHARMACEUTICALS, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LAUMAS, SANDEEP;REEL/FRAME:056359/0869 Effective date: 20200415 Owner name: 9 METERS BIOPHARMA, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MADAN, JAY;REEL/FRAME:056359/0858 Effective date: 20210505
2021-10-28	STPP	Information on status: patent application and granting procedure in general	Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION
2022-08-26	STPP	Information on status: patent application and granting procedure in general	Free format text: NON FINAL ACTION MAILED
2022-09-26	STCB	Information on status: application discontinuation	Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION
2023-04-10	AS	Assignment	Owner name: HIGH TRAIL SPECIAL SITUATIONS LLC, NEW JERSEY Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:9 METERS BIOPHARMA, INC.;NAIA RARE DISEASES, LLC;REEL/FRAME:063281/0653 Effective date: 20220715